Amylyx Pharmaceuticals, Inc. Marketable Securities (Current)
Amylyx Pharmaceuticals, Inc. (AMLX) had Marketable Securities (Current) of $201.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $201.43M.
- 2026-03-31: Marketable Securities, Current $50.63M.
- 2025-12-31: Marketable Securities, Current $90.33M.
- 2025-09-30: Marketable Securities, Current $118.81M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $201.43M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $50.63M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $90.33M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $118.81M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $122.74M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $144.30M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $99.11M 10-K · filed 2026-03-03 |
| 2024-09-30 | $162.56M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $201.16M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |